Tags

Type your tag names separated by a space and hit enter

Therapeutic potential of endocannabinoid-hydrolysing enzyme inhibitors.
Basic Clin Pharmacol Toxicol 2007; 101(5):287-93BC

Abstract

The specific protein target of delta9-tetrahydrocannabinol (delta9-THC), the main active ingredient of Cannabis sativa L., was characterized from rat brain nearly 20 years ago, and several endogenous compounds and proteins comprising the endocannabinoid (eCB) system have since been discovered. It has become evident that the eCB system consists of at least two cannabinoid receptors (i.e. the CB1 and CB2 receptors), in addition to their endogenous ligands (the eCBs) and several enzymes involved in the biosynthesis and catabolism of the eCBs. The two well-established eCBs, N-arachidonoylethanolamide (AEA) and 2-arachidonoylglycerol (2-AG), are produced by neurons on demand, act near their sites of synthesis and are effectively metabolized by fatty acid amide hydrolase (FAAH) and monoglyceride lipase (MGL), respectively. Inhibitors specifically targeting these enzymes could offer novel therapeutic approaches (e.g. for the treatment of pain and movement disorders). This MiniReview summarizes the literature concerning the potential therapeutic potential of FAAH and MGL inhibitors.

Authors+Show Affiliations

Department of Pharmaceutical Chemistry, University of Kuopio, Kuopio, Finland. susanna.saario@uku.fiNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

17910610

Citation

Saario, Susanna M., and Jarmo T. Laitinen. "Therapeutic Potential of Endocannabinoid-hydrolysing Enzyme Inhibitors." Basic & Clinical Pharmacology & Toxicology, vol. 101, no. 5, 2007, pp. 287-93.
Saario SM, Laitinen JT. Therapeutic potential of endocannabinoid-hydrolysing enzyme inhibitors. Basic Clin Pharmacol Toxicol. 2007;101(5):287-93.
Saario, S. M., & Laitinen, J. T. (2007). Therapeutic potential of endocannabinoid-hydrolysing enzyme inhibitors. Basic & Clinical Pharmacology & Toxicology, 101(5), pp. 287-93.
Saario SM, Laitinen JT. Therapeutic Potential of Endocannabinoid-hydrolysing Enzyme Inhibitors. Basic Clin Pharmacol Toxicol. 2007;101(5):287-93. PubMed PMID: 17910610.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Therapeutic potential of endocannabinoid-hydrolysing enzyme inhibitors. AU - Saario,Susanna M, AU - Laitinen,Jarmo T, PY - 2007/10/4/pubmed PY - 2007/12/6/medline PY - 2007/10/4/entrez SP - 287 EP - 93 JF - Basic & clinical pharmacology & toxicology JO - Basic Clin. Pharmacol. Toxicol. VL - 101 IS - 5 N2 - The specific protein target of delta9-tetrahydrocannabinol (delta9-THC), the main active ingredient of Cannabis sativa L., was characterized from rat brain nearly 20 years ago, and several endogenous compounds and proteins comprising the endocannabinoid (eCB) system have since been discovered. It has become evident that the eCB system consists of at least two cannabinoid receptors (i.e. the CB1 and CB2 receptors), in addition to their endogenous ligands (the eCBs) and several enzymes involved in the biosynthesis and catabolism of the eCBs. The two well-established eCBs, N-arachidonoylethanolamide (AEA) and 2-arachidonoylglycerol (2-AG), are produced by neurons on demand, act near their sites of synthesis and are effectively metabolized by fatty acid amide hydrolase (FAAH) and monoglyceride lipase (MGL), respectively. Inhibitors specifically targeting these enzymes could offer novel therapeutic approaches (e.g. for the treatment of pain and movement disorders). This MiniReview summarizes the literature concerning the potential therapeutic potential of FAAH and MGL inhibitors. SN - 1742-7835 UR - https://www.unboundmedicine.com/medline/citation/17910610/Therapeutic_potential_of_endocannabinoid_hydrolysing_enzyme_inhibitors_ L2 - https://doi.org/10.1111/j.1742-7843.2007.00130.x DB - PRIME DP - Unbound Medicine ER -